Literature DB >> 28796347

Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas.

Gauri Panse1, John Sa Chrisinger1, Cheuk H Leung2, Davis R Ingram3, Samia Khan3, Khalida Wani3, Heather Lin2, Alexander J Lazar1,3, Wei-Lien Wang1,3.   

Abstract

AIMS: Multiple genetic alterations, including alternative lengthening of telomeres (ALT) and NOTCH mutations, have been described in angiosarcoma. Loss of α-thalassaemia/mental retardation syndrome X-linked (ATRX) and death domain-associated protein 6 (DAXX) expression is frequently associated with the ALT phenotype. Additionally, inhibition of NOTCH signalling induces the development of malignant vascular tumours in mice, indicating a tumour suppressive role of the NOTCH pathway in the pathogenesis of angiosarcoma. The aim of this study was to evaluate the immunohistochemical expression of ATRX, DAXX and NOTCH receptors (NOTCH1 and NOTCH2) in a large cohort of angiosarcomas, and study their clinicopathological and prognostic significance. METHODS AND
RESULTS: One hundred and forty cases of angiosarcoma were stained for ATRX, DAXX, NOTCH1 and NOTCH2. ATRX loss (<10% labelling) was seen in seven of 118 (6%) cases, and was more frequent in deep soft tissue tumours than in other body sites (P = 0.004). Angiosarcomas with ATRX loss were associated with worse event-free survival than angiosarcomas with retained ATRX expression (P = 0.003). DAXX was retained in all specimens examined. Decreased NOTCH1 expression (≤1+ intensity) was seen in 29 of 123 (24%) cases, and was associated with a cutaneous site of origin (P = 0.013) and advanced disease (P = 0.026). NOTCH2 expression was decreased in 16 of 103 (16%) cases, was associated with visceral tumours (P = 0.001), and correlated with worse disease-specific survival (P = 0.033).
CONCLUSIONS: ATRX, NOTCH1 and NOTCH2 expression varies in angiosarcomas and shows significant correlations with site of origin and poor clinical outcome, thus highlighting the biological heterogeneity within this tumour type.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  ATRX; DAXX; NOTCH1; NOTCH2; angiosarcoma

Mesh:

Substances:

Year:  2017        PMID: 28796347     DOI: 10.1111/his.13337

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

Review 1.  Angiosarcomas: histology, immunohistochemistry and molecular insights with implications for differential diagnosis.

Authors:  Isidro Machado; Francisco Giner; Javier Lavernia; Julia Cruz; Víctor Traves; Celia Requena; Beatriz Llombart; José Antonio López-Guerrero; Antonio Llombart-Bosch
Journal:  Histol Histopathol       Date:  2020-09-04       Impact factor: 2.303

Review 2.  Dynamic Activity of Histone H3-Specific Chaperone Complexes in Oncogenesis.

Authors:  Ting Wen; Qiao Yi Chen
Journal:  Front Oncol       Date:  2022-01-11       Impact factor: 6.244

3.  Notch2 signal is required for the maintenance of canine hemangiosarcoma cancer stem cell-like cells.

Authors:  Keisuke Aoshima; Yuki Fukui; Kevin Christian Montecillo Gulay; Ochbayar Erdemsurakh; Atsuya Morita; Atsushi Kobayashi; Takashi Kimura
Journal:  BMC Vet Res       Date:  2018-10-03       Impact factor: 2.741

4.  A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes.

Authors:  Cao Jin; Sean Hacking; Miglena K Komforti; Mansoor Nasim
Journal:  Biomark Insights       Date:  2019-07-23

Review 5.  ALT Positivity in Human Cancers: Prevalence and Clinical Insights.

Authors:  Danny MacKenzie; Andrea K Watters; Julie T To; Melody W Young; Jonathan Muratori; Marni H Wilkoff; Rita G Abraham; Maria M Plummer; Dong Zhang
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

6.  Comparison of the oncogenomic landscape of canine and feline hemangiosarcoma shows novel parallels with human angiosarcoma.

Authors:  Kim Wong; Latasha Ludwig; Oscar Krijgsman; David J Adams; Geoffrey A Wood; Louise van der Weyden
Journal:  Dis Model Mech       Date:  2021-07-23       Impact factor: 5.758

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.